IMMY20043/ HPN217 /Brea Lipe
Basic Study Information
Purpose:
An open-label, Phase 1/2 study of HPN217 as monotherapy to assess the safety, tolerability
and PK in patients with relapsed/ refractory multiple myeloma
Location: University of Rochester James P Wilmot Cancer Institute
Lead Researcher (Principal Investigator)
Lead Researcher:
Brea Lipe
Study Contact Information
Study Coordinator: Lauren Mitchell
Email: lauren_mitchell@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search